View Older Stories View More Recent Stories
-
Best Stocks To Buy Now In 2022? 4 Dividend Stocks For Your Watchlist
-
AgroFresh Solutions to Participate in the BMO Capital Markets Global Farm to Market Conference
-
The Future of Food: BMO Hosts Leading Farm to Market Conference in New York
-
UPDATE: BMO Capital Downgrades Switch Inc. (SWCH) to Market Perform
-
Orchid Island Capital Announces May 2022 Monthly Dividend and April 30, 2022 RMBS Portfolio Characteristics
-
Sandstorm Gold Royalties Announces Record 2022 First Quarter Results
-
UPDATE: PolyPid Ltd. (PYPD) PT Lowered to $27 at BMO Capital
-
Bunge CEO to Join BMO Capital Markets Farm to Market Conference in New York City
-
Atalaya Mining PLC Announces Notice of Unaudited Q1 2022 Results
-
BMO Expands Electronic Trading Operations for Institutions and Broker Dealers to EMEA Markets
-
CIGNA (CI) PT Raised to $320, Reiterated Top Pick at BMO Capital
-
Chuy's Holdings (CHUY) PT Lowered to $28 at BMO Capital
-
Adtalem Global Education (ATGE) PT Raised to $38 at BMO Capital
-
Canada's April jobless rate dips to 5.2%, jobs growth less then expected
-
Under Armour profit to take hit from higher costs, China curbs; shares tank
-
Ionis Pharmaceuticals (IONS) Reports Strong 1Q, Eplontersen PN Data Soon - BMO Capital
-
EOG Resources (EOG) Beats and Declares a Special Dividend, BMO Capital Reiterates Outperform
-
ADM Chairman and CEO Juan Luciano, CFO Vikram Luthar to Discuss Strategy, Growth Opportunities at 17th Annual BMO Capital Markets Farm to Market Conference
-
Acadia Healthcare (ACHC) PT Raised to $82 at BMO Capital
-
Chipmaker MaxLinear to buy Taiwan's Silicon Motion for about $4 billion
-
MaxLinear (MXL) Acquires Silicon Motion (SIMO) at EV of $8B
-
MaxLinear to Acquire Silicon Motion
-
Sunrun (RUN) Has The Ability to Raise Prices Significantly as Utilities Do - BMO Capital
-
Canadian dollar seen rebounding as high oil price feeds trade surplus: Reuters poll
-
The Future of Food: BMO Hosts Leading Farm to Market Conference in New York
-
BMO Capital Maintains Underperform Rating on Neurocrine Bio (NBIX), "Outlook for Ingrezza Has Not Changed"
-
BMO Capital Reiterates Outperform Rating, $780 Price Target on Regeneron Pharma (REGN), Awaits Key Data from Oncology Programs
-
AMD (AMD) Beats and Raises but BMO Capital Reiterates Market Perform Rating
-
HEXO Corp. (HEXO) Launches $40M Launches At-the-Market Offering
-
HEXO Launches New At-the-Market Offering
-
HEXO Launches New At-the-Market Offering
-
Hayward (HAYW) Prices Secondary Offering of 24,000,000 Shares of Common Stock by Selling Stockholders and Repurchase of Common Stock
-
Hayward Holdings Announces Pricing of Secondary Offering of 24,000,000 Shares of Common Stock by Selling Stockholders and Repurchase of Common Stock
-
BMO Capital Reiterates Market Perform Rating on Biogen (BIIB), "Encouraged with Potential New Leadership... Remain on Sidelines Given Risk Into Lecanemab Data"
-
BMO Capital Upgrades Sundial Growers (SNDL) to Market Perform Following Recent Decline
-
UPDATE: BMO Capital Upgrades JAKKS Pacific (JAKK) to Outperform
-
Royalty North Strengthens Copper Portfolio with Proposed Acquisition of Antamina NPI as Part of Previously Announced Reverse Takeover Transaction with Sandstorm Gold
-
Fertilizer sector set for biggest profits in years on Russia-Ukraine conflict
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $92 at BMO Capital on Camzyos Approval
-
SANDSTORM GOLD ROYALTIES ANNOUNCES US$1.1 BILLION PORTFOLIO TRANSFORMATION THROUGH ACQUISITIONS OF NOMAD ROYALTY COMPANY AND BASECORE PORTFOLIO
-
UPDATE: BMO Capital Downgrades Weyerhaeuser (WY) to Market Perform
-
MCC Toronto Announces Naming of Paul Austin Human Rights Centre
-
UPDATE: Amazon.com (AMZN) PT Lowered to $3,450 at BMO Capital After Margin Expansion is Pushed Out
-
BMO Capital Reiterates Outperform Rating on Bristol-Myers Squibb Co. (BMY)
-
T. Rowe Price (TROW) PT Lowered to $160 at BMO Capital
-
UPDATE: Twitter, Inc. (TWTR) PT Raised to $54 at BMO Capital
-
Dollar dips, U.S. stocks tumble on inflation concerns
-
BMO Capital Reiterates Market Perform Rating, $64 Price Target on Gilead Sciences (GILD) Following Q1 Report, "Continue to See Gilead at a Crossroads"
-
Gilead earnings beat Street estimates, writedown taken on cancer drug
-
Orchid Island Capital Announces First Quarter 2022 Results

